Vir Biotechnology, Inc. Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests
Vir Biotechnology, Inc. (VIR) reported Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests of $100.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Shareholders' Equity
us-gaap:MinorityInterestDecreaseFromRedemptions · last filed 2026-02-23
- Vir Biotechnology, Inc. noncontrolling interest, decrease from redemptions or purchase of interests for the quarter ending 2023-12-31 was $0.00.
- Vir Biotechnology, Inc. noncontrolling interest, decrease from redemptions or purchase of interests for the quarter ending 2023-09-30 was $0.00.
- Vir Biotechnology, Inc. noncontrolling interest, decrease from redemptions or purchase of interests for the quarter ending 2023-06-30 was $100.00K.
- Vir Biotechnology, Inc. noncontrolling interest, decrease from redemptions or purchase of interests for fiscal 2023 was $100.00K.
| Period end | Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 3 month | Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 6 month | Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 9 month | Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $100.00K derived: sum of 3 quarters · filed 2026-02-23 | $100.00K 10-K · filed 2026-02-23 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $100.00K derived: sum of 2 quarters · filed 2024-11-04 | $100.00K 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $100.00K 10-Q · filed 2024-08-01 | $100.00K 10-Q · filed 2024-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |